RU2627639C2 - Способ и офтальмологическое устройство гальванического лечения глаз - Google Patents
Способ и офтальмологическое устройство гальванического лечения глаз Download PDFInfo
- Publication number
- RU2627639C2 RU2627639C2 RU2015102838A RU2015102838A RU2627639C2 RU 2627639 C2 RU2627639 C2 RU 2627639C2 RU 2015102838 A RU2015102838 A RU 2015102838A RU 2015102838 A RU2015102838 A RU 2015102838A RU 2627639 C2 RU2627639 C2 RU 2627639C2
- Authority
- RU
- Russia
- Prior art keywords
- current
- eye
- aforementioned
- erosion
- supply
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 43
- 230000005684 electric field Effects 0.000 claims abstract description 26
- 230000003287 optical effect Effects 0.000 claims abstract description 26
- 230000003628 erosive effect Effects 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims description 41
- 239000013543 active substance Substances 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 7
- 230000007794 irritation Effects 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 238000012536 packaging technology Methods 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 230000007646 directional migration Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 55
- 208000027418 Wounds and injury Diseases 0.000 description 55
- 239000010410 layer Substances 0.000 description 43
- 239000000463 material Substances 0.000 description 25
- 239000000758 substrate Substances 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 11
- 238000004891 communication Methods 0.000 description 10
- 210000004087 cornea Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 238000012937 correction Methods 0.000 description 7
- 239000010409 thin film Substances 0.000 description 7
- 206010011013 Corneal erosion Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 238000013500 data storage Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000002924 anti-infective effect Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000001860 Eye Infections Diseases 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000011323 eye infectious disease Diseases 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 229910001416 lithium ion Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000003990 capacitor Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 239000002346 layers by function Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000052 poly(p-xylylene) Polymers 0.000 description 2
- -1 propanidine Chemical compound 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000000565 sealant Substances 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010292 electrical insulation Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000848 foscarnet sodium Drugs 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- DQRZDIMTJNNJHB-UHFFFAOYSA-N isis 2922 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(O)=S)C(OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DQRZDIMTJNNJHB-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009718 spray deposition Methods 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- FEPTXVIRMZIGFY-UHFFFAOYSA-N sulfisoxazole diolamine Chemical compound OCCNCCO.CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C FEPTXVIRMZIGFY-UHFFFAOYSA-N 0.000 description 1
- 229940032483 sulfisoxazole diolamine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 1
- 230000016776 visual perception Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0468—Specially adapted for promoting wound healing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36046—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the eye
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
- A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Eyeglasses (AREA)
- Electrotherapy Devices (AREA)
- Prostheses (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Eye Examination Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665964P | 2012-06-29 | 2012-06-29 | |
| US61/665,964 | 2012-06-29 | ||
| PCT/US2013/048213 WO2014004845A1 (en) | 2012-06-29 | 2013-06-27 | Method and ophthalmic device for galvanic healing of an eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015102838A RU2015102838A (ru) | 2016-08-20 |
| RU2627639C2 true RU2627639C2 (ru) | 2017-08-09 |
Family
ID=48771766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015102838A RU2627639C2 (ru) | 2012-06-29 | 2013-06-27 | Способ и офтальмологическое устройство гальванического лечения глаз |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9801758B2 (enExample) |
| EP (1) | EP2866885A1 (enExample) |
| JP (2) | JP6239610B2 (enExample) |
| KR (1) | KR101964582B1 (enExample) |
| CN (1) | CN104780970B (enExample) |
| AU (1) | AU2013280242B2 (enExample) |
| BR (1) | BR112014032920A2 (enExample) |
| CA (1) | CA2877361A1 (enExample) |
| HK (1) | HK1210076A1 (enExample) |
| IL (1) | IL236370A0 (enExample) |
| IN (1) | IN2014DN11182A (enExample) |
| MX (1) | MX347468B (enExample) |
| MY (1) | MY188854A (enExample) |
| RU (1) | RU2627639C2 (enExample) |
| SG (2) | SG10201610766QA (enExample) |
| WO (1) | WO2014004845A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9475709B2 (en) | 2010-08-25 | 2016-10-25 | Lockheed Martin Corporation | Perforated graphene deionization or desalination |
| US10005038B2 (en) | 2014-09-02 | 2018-06-26 | Lockheed Martin Corporation | Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same |
| US10980919B2 (en) | 2016-04-14 | 2021-04-20 | Lockheed Martin Corporation | Methods for in vivo and in vitro use of graphene and other two-dimensional materials |
| US9744617B2 (en) | 2014-01-31 | 2017-08-29 | Lockheed Martin Corporation | Methods for perforating multi-layer graphene through ion bombardment |
| US10376845B2 (en) | 2016-04-14 | 2019-08-13 | Lockheed Martin Corporation | Membranes with tunable selectivity |
| US9610546B2 (en) | 2014-03-12 | 2017-04-04 | Lockheed Martin Corporation | Separation membranes formed from perforated graphene and methods for use thereof |
| US10203295B2 (en) | 2016-04-14 | 2019-02-12 | Lockheed Martin Corporation | Methods for in situ monitoring and control of defect formation or healing |
| US10653824B2 (en) | 2012-05-25 | 2020-05-19 | Lockheed Martin Corporation | Two-dimensional materials and uses thereof |
| US9834809B2 (en) | 2014-02-28 | 2017-12-05 | Lockheed Martin Corporation | Syringe for obtaining nano-sized materials for selective assays and related methods of use |
| US8857981B2 (en) * | 2012-07-26 | 2014-10-14 | Google Inc. | Facilitation of contact lenses with capacitive sensors |
| US9592475B2 (en) | 2013-03-12 | 2017-03-14 | Lockheed Martin Corporation | Method for forming perforated graphene with uniform aperture size |
| US9572918B2 (en) | 2013-06-21 | 2017-02-21 | Lockheed Martin Corporation | Graphene-based filter for isolating a substance from blood |
| EP3099645A4 (en) | 2014-01-31 | 2017-09-27 | Lockheed Martin Corporation | Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer |
| CA2938273A1 (en) | 2014-01-31 | 2015-08-06 | Peter V. Bedworth | Perforating two-dimensional materials using broad ion field |
| CA2942496A1 (en) | 2014-03-12 | 2015-09-17 | Lockheed Martin Corporation | Separation membranes formed from perforated graphene |
| US9907498B2 (en) * | 2014-09-04 | 2018-03-06 | Verily Life Sciences Llc | Channel formation |
| KR102271817B1 (ko) * | 2014-09-26 | 2021-07-01 | 삼성전자주식회사 | 증강현실을 위한 스마트 콘택렌즈와 그 제조 및 동작방법 |
| US10031348B2 (en) | 2014-10-15 | 2018-07-24 | California Institute Of Technology | Contact lens with metered liquid system |
| US9937074B2 (en) * | 2015-01-22 | 2018-04-10 | Eyegate Pharmaceuticals, Inc. | Iontophoretic contact lens |
| AU2016303048A1 (en) | 2015-08-05 | 2018-03-01 | Lockheed Martin Corporation | Perforatable sheets of graphene-based material |
| MX2018001559A (es) | 2015-08-06 | 2018-09-27 | Lockheed Corp | Modificacion de nanoparticula y perforacion de grafeno. |
| US20170081954A1 (en) * | 2015-09-23 | 2017-03-23 | Tesco Corporation | Pipe joint location detection system and method |
| WO2017070528A1 (en) | 2015-10-23 | 2017-04-27 | California Institute Of Technology | Reliable deposition of thin parylene |
| ITUB20154761A1 (it) * | 2015-10-29 | 2017-04-29 | Resono Ophthalmic S R L | Sistema di elettrodo e relativo dispositivo per il trattamento di patologie dell?occhio, in particolare dell?occhio secco |
| EP3442697A4 (en) | 2016-04-14 | 2020-03-18 | Lockheed Martin Corporation | SELECTIVE INTERFACE REDUCTION OF GRAPH DEFECTS |
| CA3020874A1 (en) | 2016-04-14 | 2017-10-19 | Lockheed Martin Corporation | Two-dimensional membrane structures having flow passages |
| CA3020686A1 (en) | 2016-04-14 | 2017-10-19 | Lockheed Martin Corporation | Method for treating graphene sheets for large-scale transfer using free-float method |
| EP3533488B1 (en) * | 2016-10-31 | 2021-05-26 | Y-Brain Inc | Electrical stimulation apparatus comprising current monitoring apparatus |
| KR101963021B1 (ko) * | 2017-04-14 | 2019-03-27 | 한양대학교 산학협력단 | 다채널 안구 이온 영동 장치 및 방법 |
| US11029538B2 (en) | 2017-10-25 | 2021-06-08 | Coopervision International Limited | Contact lenses having an ion-impermeable portion and related methods |
| WO2019177540A1 (en) * | 2018-03-14 | 2019-09-19 | Menicon Singapore Pte Ltd. | Wearable device for communication with an ophthalmic device |
| WO2019226682A1 (en) | 2018-05-22 | 2019-11-28 | California Institute Of Technology | Miniature fixed and adjustable flow restrictor for the body |
| CN112351771A (zh) | 2018-06-11 | 2021-02-09 | 加州理工学院 | 具有环状形状的眼睛治疗设备 |
| US11147712B2 (en) * | 2018-09-09 | 2021-10-19 | Shawn Michael Vuong | Ocular shield for facilitating generation of visual evoked potentials (VEP) |
| TWI680692B (zh) * | 2018-09-21 | 2019-12-21 | 魔力歐生技有限公司 | 具非對稱電流之切換控制裝置 |
| US11550166B2 (en) | 2019-06-05 | 2023-01-10 | Coopervision International Limited | Contact lenses with microchannels |
| JP7618647B2 (ja) * | 2020-03-26 | 2025-01-21 | 株式会社シード | 電子装置、電子部品、コンタクトレンズ型電子装置、及び電子装置の製造方法 |
| CN113398471B (zh) * | 2021-07-28 | 2022-08-23 | 浙江京兆医疗器械有限公司 | 一种用于辅助控制眼部病症的方法及设备 |
| KR102431963B1 (ko) | 2022-04-19 | 2022-08-16 | 주식회사 셀리코 | 각막 신경 자극이 가능한 콘택트 렌즈의 제조 방법 |
| KR102556314B1 (ko) | 2022-08-08 | 2023-07-17 | 주식회사 셀리코 | 안구 신경 자극이 가능한 코일선을 갖는 콘택트 렌즈의 제조 방법 |
| CN115501478B (zh) * | 2022-09-19 | 2025-09-09 | 电子科技大学 | 一种用于角膜损伤修复的柔性压电角膜接触镜 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070260171A1 (en) * | 2005-09-27 | 2007-11-08 | Higuchi John W | Intraocular iontophoretic device and associated methods |
| US20090264966A1 (en) * | 2004-11-02 | 2009-10-22 | Pixeloptics, Inc. | Device for Inductive Charging of Implanted Electronic Devices |
| WO2010036966A1 (en) * | 2008-09-26 | 2010-04-01 | The Cleveland Clinic Foundation | Apparatus and method for delivering a therapeutic agent to ocular tissue |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4895154A (en) | 1988-02-19 | 1990-01-23 | Staodynamics, Inc. | Electronic stimulating device for enhanced healing of soft tissue wounds |
| US6544193B2 (en) * | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
| US6479890B1 (en) | 1998-01-22 | 2002-11-12 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Semiconductor microsystem embedded in flexible foil |
| US6617671B1 (en) | 1999-06-10 | 2003-09-09 | Micron Technology, Inc. | High density stackable and flexible substrate-based semiconductor device modules |
| US20020035358A1 (en) * | 2000-05-09 | 2002-03-21 | Ming Wang | Pulsed electromagnetic field therapy for treatment of corneal disorders and injuries |
| US20040106965A1 (en) * | 2001-06-29 | 2004-06-03 | Chow Alan Y. | Methods and apparatus for treatment of degenerative retinal disease via indirect electrical stimulation |
| US20050004625A1 (en) * | 2001-06-29 | 2005-01-06 | Chow Alan Y. | Treatment of degenerative retinal disease via electrical stimulation of surface structures |
| US6721602B2 (en) * | 2001-08-21 | 2004-04-13 | Medtronic, Inc. | Implantable medical device assembly and manufacturing method |
| FR2840533B1 (fr) * | 2002-06-11 | 2005-04-15 | Guinot | Dispositif d'ionophorese transcutanee utilisant un champ electrique de surface |
| CA2496265A1 (en) | 2002-08-20 | 2004-03-04 | E-Vision, Llc | Method of manufacturing an electro-active lens |
| US20060167435A1 (en) * | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
| US7321795B2 (en) * | 2003-03-24 | 2008-01-22 | Les Bogdanowicz | Compositions for electric stimulation of the eye |
| WO2005077452A1 (en) * | 2004-02-06 | 2005-08-25 | Scyfix Llc | Treatment of vision disorders using electrical, light, and/or sound energy |
| US7457667B2 (en) * | 2004-02-19 | 2008-11-25 | Silverleaf Medical Products, Inc. | Current producing surface for a wound dressing |
| US20060089590A1 (en) * | 2004-10-27 | 2006-04-27 | John Higuchi | Methods and devices for sustained in-vivo release of an active agent |
| US20060204548A1 (en) * | 2005-03-01 | 2006-09-14 | Allergan, Inc. | Microimplants for ocular administration |
| US20070093877A1 (en) * | 2005-10-26 | 2007-04-26 | Beecham Michael C | System for maintaining normal health of retinal cells and promoting regeneration of retinal cells |
| CN201094807Y (zh) * | 2007-07-13 | 2008-08-06 | 龙丹 | 创伤疼痛愈合止痛敷贴仪 |
| WO2009110470A1 (ja) * | 2008-03-03 | 2009-09-11 | 国立大学法人 長崎大学 | 角膜経上皮電気抵抗値の測定方法 |
| US20100076553A1 (en) * | 2008-09-22 | 2010-03-25 | Pugh Randall B | Energized ophthalmic lens |
-
2013
- 2013-06-27 KR KR1020157001918A patent/KR101964582B1/ko not_active Expired - Fee Related
- 2013-06-27 CN CN201380044987.0A patent/CN104780970B/zh not_active Expired - Fee Related
- 2013-06-27 MX MX2015000019A patent/MX347468B/es active IP Right Grant
- 2013-06-27 SG SG10201610766QA patent/SG10201610766QA/en unknown
- 2013-06-27 BR BR112014032920A patent/BR112014032920A2/pt not_active Application Discontinuation
- 2013-06-27 IN IN11182DEN2014 patent/IN2014DN11182A/en unknown
- 2013-06-27 US US13/928,689 patent/US9801758B2/en not_active Expired - Fee Related
- 2013-06-27 HK HK15110822.6A patent/HK1210076A1/xx unknown
- 2013-06-27 MY MYPI2014703975A patent/MY188854A/en unknown
- 2013-06-27 WO PCT/US2013/048213 patent/WO2014004845A1/en not_active Ceased
- 2013-06-27 SG SG11201408712YA patent/SG11201408712YA/en unknown
- 2013-06-27 RU RU2015102838A patent/RU2627639C2/ru not_active IP Right Cessation
- 2013-06-27 CA CA2877361A patent/CA2877361A1/en not_active Abandoned
- 2013-06-27 AU AU2013280242A patent/AU2013280242B2/en not_active Ceased
- 2013-06-27 JP JP2015520509A patent/JP6239610B2/ja not_active Expired - Fee Related
- 2013-06-27 EP EP13735173.0A patent/EP2866885A1/en not_active Withdrawn
-
2014
- 2014-12-21 IL IL236370A patent/IL236370A0/en unknown
-
2017
- 2017-08-22 JP JP2017159204A patent/JP6430602B2/ja not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090264966A1 (en) * | 2004-11-02 | 2009-10-22 | Pixeloptics, Inc. | Device for Inductive Charging of Implanted Electronic Devices |
| US20070260171A1 (en) * | 2005-09-27 | 2007-11-08 | Higuchi John W | Intraocular iontophoretic device and associated methods |
| WO2010036966A1 (en) * | 2008-09-26 | 2010-04-01 | The Cleveland Clinic Foundation | Apparatus and method for delivering a therapeutic agent to ocular tissue |
Also Published As
| Publication number | Publication date |
|---|---|
| US9801758B2 (en) | 2017-10-31 |
| US20140005514A1 (en) | 2014-01-02 |
| HK1210076A1 (en) | 2016-04-15 |
| JP6430602B2 (ja) | 2018-11-28 |
| MX2015000019A (es) | 2015-08-20 |
| RU2015102838A (ru) | 2016-08-20 |
| IL236370A0 (en) | 2015-02-26 |
| EP2866885A1 (en) | 2015-05-06 |
| SG11201408712YA (en) | 2015-02-27 |
| JP2015525619A (ja) | 2015-09-07 |
| JP2017200661A (ja) | 2017-11-09 |
| CN104780970A (zh) | 2015-07-15 |
| MY188854A (en) | 2022-01-10 |
| CN104780970B (zh) | 2019-08-13 |
| KR101964582B1 (ko) | 2019-04-03 |
| AU2013280242A1 (en) | 2015-02-19 |
| IN2014DN11182A (enExample) | 2015-10-02 |
| MX347468B (es) | 2017-04-26 |
| BR112014032920A2 (pt) | 2017-06-27 |
| KR20150027810A (ko) | 2015-03-12 |
| SG10201610766QA (en) | 2017-02-27 |
| JP6239610B2 (ja) | 2017-11-29 |
| WO2014004845A1 (en) | 2014-01-03 |
| CA2877361A1 (en) | 2014-01-03 |
| AU2013280242B2 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101964582B1 (ko) | 눈의 갈바닉 치유를 위한 안과용 기구 | |
| TWI619470B (zh) | 具神經頻率偵測系統之眼用鏡片 | |
| TWI620543B (zh) | 具眼內壓監測系統之眼用鏡片 | |
| US9764150B2 (en) | Contact lens for increasing tear production | |
| US9901322B2 (en) | Ophthalmic lens with retinal vascularization monitoring system | |
| JP2021528175A (ja) | 眼に装着可能な治療デバイス、ならびに関連するシステムおよび方法 | |
| US20180228648A1 (en) | Method and ophthalmic device with active agent release system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190628 |